Northera Shortage: What Providers and Prescribers Need to Know in 2026

For clinicians managing patients with neurogenic orthostatic hypotension (nOH), Droxidopa (Northera) remains a cornerstone therapy. However, patient reports of difficulty filling prescriptions have raised questions about supply continuity. This briefing provides an evidence-based overview of Northera's current availability, prescribing implications, and practical resources for your practice.

Current Shortage Status

As of early 2026, Droxidopa is not listed on the FDA Drug Shortage Database or the ASHP drug shortage list. There is no active manufacturing disruption affecting the brand or generic formulations.

However, patient-reported access barriers persist. These are primarily driven by:

• Low routine stocking at retail pharmacies due to niche patient population
• Specialty pharmacy distribution requirements for brand-name Northera
• Prior authorization and step therapy mandates from most payers
• Patient confusion about generic availability and pharmacy sourcing

The distinction between a formal shortage and practical accessibility is important when counseling patients who report being unable to fill their prescriptions.

Timeline and Background

Droxidopa was first approved by the FDA in February 2014 under the brand name Northera, marketed by Lundbeck NA Ltd (originally Chelsea Therapeutics). Key milestones:

• 2014: FDA approval for symptomatic nOH in adults with primary autonomic failure (Parkinson's disease, MSA, PAF), dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy
• February 2021: First generic Droxidopa approvals (multiple manufacturers including Aurobindo, Alkem, Sun Pharma, Zydus, and others)
• 2021-2026: 11+ generic manufacturers approved, broadening supply chain and reducing costs

The entry of multiple generics has substantially improved supply resilience, though individual pharmacy stocking remains inconsistent due to the relatively small patient population.

Prescribing Implications

Dosing and Administration

Northera is available as 100 mg, 200 mg, and 300 mg oral capsules. The recommended starting dose is 100 mg three times daily, titrated in 100 mg increments every 24-48 hours based on symptomatic response, up to a maximum of 600 mg three times daily (1,800 mg/day).

Critical prescribing points:

• The final daily dose must be taken at least 3 hours before bedtime to mitigate supine hypertension risk
• Capsules should be swallowed whole, taken consistently with or without food
• Effectiveness beyond 2 weeks has not been established in clinical trials — periodic reassessment of continued need is recommended per the FDA label
• No dose adjustment is required for renal or hepatic impairment

Boxed Warning: Supine Hypertension

Droxidopa carries a boxed warning for supine hypertension, which can increase the risk of stroke, myocardial infarction, and death. Providers should:

• Monitor supine blood pressure prior to and during treatment
• Advise patients to elevate the head of the bed 10-20 degrees
• Ensure the last dose is taken ≥3 hours before bedtime
• Consider discontinuation or dose reduction if supine hypertension becomes clinically significant

Drug Interactions of Clinical Relevance

No dedicated drug interaction studies have been conducted for Droxidopa. Key considerations include:

• Dopa-decarboxylase inhibitors (carbidopa): May reduce conversion of Droxidopa to norepinephrine, potentially requiring dose adjustment. Many nOH patients are on carbidopa/levodopa for Parkinson's disease
• MAO-B inhibitors (rasagiline, selegiline): Were permitted in Phase 3 trials; clinical monitoring advised
• Non-selective MAO inhibitors: Avoid — risk of hypertensive crisis
• Other sympathomimetic agents: Additive hypertensive effects possible

For a comprehensive review, see our article on Northera drug interactions.

Availability Picture

Generic Droxidopa is manufactured by 11+ companies. Despite this robust manufacturing base, retail pharmacy availability remains inconsistent because:

• Annual prescriptions for Droxidopa are a fraction of high-volume medications
• Pharmacy purchasing algorithms deprioritize low-demand items
• Many pharmacies require special ordering (1-3 business day turnaround from wholesalers)

Specialty pharmacies and independent pharmacies serving neurological patient populations tend to maintain more reliable stock.

Cost and Access

Cost remains a barrier for many patients:

• Brand-name Northera: $3,100 to $11,250/month retail depending on capsule strength
• Generic Droxidopa with discount card: $44-$120/month (GoodRx, SingleCare)
• Lundbeck Copay Assistance: As low as $10/month for eligible commercially insured patients
• Patient assistance programs: Prescription Hope offers $70/month for qualifying patients

Most commercial and Medicare Part D plans cover Droxidopa but require prior authorization. Step therapy (trial of Midodrine first) is commonly required. Providers can expedite access by submitting prior authorization documentation proactively and noting clinical justification for Droxidopa over alternatives.

Tools and Resources for Your Practice

• Medfinder for Providers: Help patients locate pharmacies with Droxidopa in stock. Share with your care coordination team
• Northera HCP website (northerahcp.com): Dosing guides, prior authorization templates, and prescribing information from Lundbeck
• Copay card activation: activatethecard.com/7773 — guide eligible patients to reduce out-of-pocket costs
• Prior authorization tips: Include documented diagnosis of nOH, blood pressure readings demonstrating orthostatic drop (≥20 mmHg systolic or ≥10 mmHg diastolic), and notation of why Droxidopa is preferred over Midodrine if step therapy applies

Looking Ahead

The nOH treatment landscape continues to evolve. With robust generic competition and multiple supply chain options, formal shortages of Droxidopa are unlikely in the near term. The primary challenges for patients remain practical: pharmacy stocking, insurance navigation, and cost management.

Providers can make a significant impact by:

• Writing prescriptions that allow generic substitution unless clinically contraindicated
• Proactively submitting prior authorizations
• Directing patients to tools like Medfinder for pharmacy stock checks
• Educating patients about discount cards that can reduce generic Droxidopa costs by over 95%

Final Thoughts

Northera is not in a formal shortage in 2026, but the practical challenges of filling this specialty prescription persist. Providers who understand the current landscape — and arm their patients with the right tools and resources — can significantly improve treatment continuity for this vulnerable patient population.

For additional clinical resources, see our provider's guide to helping patients find Northera and our overview of how to help patients save money on Northera.